![Rob de Ree](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rob de Ree
Directeur Général chez NorthSea Therapeutics BV
Provenance du réseau au premier degré de Rob de Ree
Entité | Type d'entité | Industrie | |
---|---|---|---|
Biogeneration Management BV
![]() Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.
14
| Subsidiary | Investment Managers | 14 |
NorthSea Therapeutics BV
![]() NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.
12
| Holding Company | Biotechnology | 12 |
SurgVision BV
![]() SurgVision BV Medical SpecialtiesHealth Technology SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands.
5
| Subsidiary | Medical Specialties | 5 |
Sirius Medical Systems BV
![]() Sirius Medical Systems BV Medical SpecialtiesHealth Technology Sirius Medical BV engages in medical industry. The firm focuses on developing medical devices for oncological surgery. The company was founded by Hubert Martens and Bram Schermers and is headquartered in Eindhoven, the Netherlands.
4
| Holding Company | Medical Specialties | 4 |
Mellon Medical BV
![]() Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.
3
| Holding Company | Medical Specialties | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Rob de Ree via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
University of Groningen | College/University | Graduate Degree Graduate Degree Masters Business Admin Doctorate Degree Graduate Degree | |
NewAmsterdam Pharma BV
![]() NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
University of Utrecht | College/University | Doctorate Degree Graduate Degree Graduate Degree | |
Forbion Capital Partners Management Holding BV
![]() Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Founder Private Equity Investor | |
Staten Biotechnology BV
![]() Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chief Executive Officer Chief Executive Officer Chief Tech/Sci/R&D Officer | |
University of Amsterdam | College/University | Undergraduate Degree Graduate Degree Corporate Officer/Principal | |
Perelman School of Medicine | College/University | Doctorate Degree Corporate Officer/Principal | |
ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
McKinsey & Co., Inc.
![]() McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin | |
BioVex Group, Inc.
![]() BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Director/Board Member Director/Board Member | |
VENTYX BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Chief Executive Officer Director/Board Member | |
University of Pennsylvania | College/University | Undergraduate Degree Undergraduate Degree | |
INKEF Capital BV
![]() INKEF Capital BV Investment ManagersFinance INKEF Capital BV is an Independent Venture Capital firm founded in 2010 by Frank R Landsberger. INKEF Capital BV is headquartered in Amsterdam. | Investment Managers | Private Equity Investor Private Equity Analyst | |
ProFibrix BV
![]() ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal | |
Hoffmann-La Roche, Inc.
![]() Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Oxyrane UK Ltd.
![]() Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NewAmsterdam Pharma Holding BV
![]() NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Founder | |
VectorY BV
![]() VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Dualyx NV
![]() Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
Escalier Biosciences BV
![]() Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Dr. Reddy's Research & Development BV
![]() Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Pharmaceuticals: Major | Founder Chief Executive Officer | |
Cristal Delivery BV
![]() Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Complement Therapeutics Ltd.
![]() Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vaccinatiezorg BV
![]() Vaccinatiezorg BV Medical/Nursing ServicesHealth Services Vaccinatiezorg BV provides infection prevention and related medical services. The private company is based in Ravenstein, Netherlands. The CEO of the Dutch company is Jan Hendrik Egberts. | Medical/Nursing Services | Chief Executive Officer | |
Rodger BV
![]() Rodger BV Medical DistributorsDistribution Services Rodger BV is a Dutch company that wholesales medical and dental instruments. The private company is based in Denekamp, Netherlands. | Medical Distributors | Director/Board Member | |
Global Healthcare Exchange LLC
![]() Global Healthcare Exchange LLC Packaged SoftwareTechnology Services Global Healthcare Exchange LLC engages in the provision of supply chain automation services for the healthcare sector. It offers E-commerce; Contracting; AP Automation; Data Management; Business Intelligence; and Compliance and Credentialing solutions. The company was founded in 2000 and is headquartered in Louisville, CO. | Packaged Software | Founder | |
PharmaCell BV
![]() PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | Biotechnology | Chief Executive Officer | |
Tens Health BV
![]() Tens Health BV Miscellaneous Commercial ServicesCommercial Services Tens Health BV provides health consulting services. The private company is based in Ravenstein, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
MediService AG
![]() MediService AG Drugstore ChainsRetail Trade MediService AG is a mail service pharmacy. The company is headquartered in Zuchwil, Switzerland. | Drugstore Chains | President | |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
InnoCore Technologies BV
![]() InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
PAION AG | Pharmaceuticals: Major | Chief Executive Officer | |
Technical University of Denmark | College/University | Graduate Degree | |
Biosyntia ApS
![]() Biosyntia ApS BiotechnologyHealth Technology Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
EpiTherapeutics ApS
![]() EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member | |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Medical Distributors | Director/Board Member | |
Alliance for Regenerative Medicine
![]() Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
Novo Seeds
![]() Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
Livingston International, Inc.
![]() Livingston International, Inc. Air Freight/CouriersTransportation Livingston International, Inc. engages in provision of customs brokerage, transportation and integrated logistics services. Its services include customs brokerage, U.S. customs brokerage, Canadian customs brokerage, Mexican customs brokerage, freight and transportation, global trade management, trade consulting, trade technology, business process services, trade sphere and vehicle transportation services. The company was founded by Gerry Livingston in 1945 and is headquartered in Toronto, Canada. | Air Freight/Couriers | Director/Board Member |
Statistiques
Internationale
Pays-Bas | 21 |
Etats-Unis | 12 |
Danemark | 9 |
Royaume-Uni | 5 |
Suède | 3 |
Sectorielle
Health Technology | 26 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 5 |
Health Services | 3 |
Opérationnelle
Director/Board Member | 202 |
Corporate Officer/Principal | 39 |
Private Equity Investor | 29 |
Independent Dir/Board Member | 25 |
Chief Executive Officer | 24 |
Relations les plus connectées
Insiders | |
---|---|
Somu Subramaniam | 49 |
Hugo Slootweg | 34 |
Jan Hendrik Egberts | 33 |
Hilde Hermansen Steineger | 24 |
Søren Møller | 21 |
Edward van Wezel | 20 |
Richard Gaster | 17 |
Alexander Vos | 17 |
Mats Blom | 15 |
Jonathan Leff | 14 |
Dirk Kersten | 14 |
Jan Frens van Giessel | 11 |
John Kastelein | 11 |
Morris J. Birnbaum | 11 |
Oskar Slotboom | 8 |
- Bourse
- Insiders
- Rob de Ree
- Connexions Sociétés